Study summary

Avutometinib plus defactinib shrank tumors in low-grade serous ovarian cancer

RAMP 201 trial · Phase 2 · Published July 2025, Journal of Clinical Oncology

44%response rate in KRAS-mutated tumors

What was tested

Avutometinib (a RAF/MEK blocker) with defactinib (a FAK blocker) for recurrent low-grade serous ovarian cancer, a rarer, slower-growing type.

What they found

Tumors shrank in 31% overall: 44% with KRAS mutations and 17% without.
Responses lasted a median of about 31 months.
Side effects led 10% to stop.

What it means

Led to the first approval specifically for KRAS-mutated low-grade serous ovarian cancer.

J Clin Oncol, via PubMed ↗ ← Back to the outlook

Last reviewed 2026-11-14 by the Find a Trial editorial team. Information on this page is for educational purposes and is not medical advice. Always consult qualified healthcare professionals about clinical trial participation.